Shots:

• The P-III TAK-620-303 (SOLSTICE) trial involves assessing TAK-620 (400mg) vs conventional antiviral therapies (IAT) in HCT and SOT recipients in a ratio (2:1) with R/R CMV infection refractory with/ out resistance- to one or a combination of the conventional antiviral therapies
• The 1EPs study shows confirmed CMV viremia clearance @ 8wk; (55% vs 26.1% in SOT recipients)- (55.9% vs 20.8% in HCT recipients)- CMV clearance regardless of baseline viral load category (62.1% & 43.9% vs 24.7% & 21.9%)- CMV viremia clearance and symptom control in transplant recipients @16wks. (18.7% vs 10.3%)
• Maribavir will be the 1st and only treatment indicated for post-transplant r/r CMV infection

 ­ Ref: Takeda | Image: The Boston Globe